Zimbabwe has declined a significant US healthcare agreement worth $367m (£272m) spanning five years over Washington's demand for sensitive information.
This rejection became public after a government memo dated December was leaked, which showed Head of State Emmerson Mnangagwa believed the deal was "unbalanced".
A government spokesperson has since clarified that the United States was seeking genetic material for research and commercial gain but was unwilling to guarantee the resulting advantages from future medical innovations.
"We will now turn to the difficult and regrettable task of winding down our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged further talks to find a agreement suitable to all parties so the nation's critical HIV treatment initiative can continue.
Broader Context
This rejection follows a similar case in Kenya, where a high court suspended a similar health funding agreement following legal challenges were raised about the safety of citizens' health data.
After resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump claimed its expenditure was "inefficient" and his administration was seeking government-to-government agreements to enhance openness and accountability.
As per reports, 16 African countries have to date agreed to similar agreements, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration might have yielded significant advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy via American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to share its genetic material and health information over an extended period, without any corresponding guarantee of benefiting from any medical innovations – like new medicines or tests – that might be developed from that provided information," Mangwana explained.
"Put simply, our country would supply the basic resources for medical research with no assurance that the final treatments would be accessible to our population if a new health crisis arise."
Sovereignty and Global Health
Mangwana further pointed out that the US's withdrawal from the global health body and its push of bilateral deals were undermining systems previously set up via the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to manage future global health emergencies.
"This system is designed to guarantee that when a nation provides its data, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the funds to develop them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We welcome further discussions with our US partners on how future collaboration could be arranged in a way that respects the independence and interests of each country."
Medical Community Reaction
Medical experts said it recognised the official position, but urged that talks need to persist since much of the country's Aids initiatives relied on foreign aid.
"In cases where specific concerns exist, such as those relating to information security or implementation frameworks, these can often be resolved via detailed discussion and negotiated safeguards," the group added.
This impasse highlights the complex debate between accepting vital international aid and safeguarding national sovereignty in an ever more interconnected world.